Frederick Schnell
Macon, GANPI 1114954310
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,148 of the $66,747 with a category attached, or 82.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2019 at $23,463 and has fallen 91.7% since, to $1,958 in 2025.
Across 108 payments — averaging $618.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Regeneron$12K
- Bristol Myers Squibb$9K
- AbbVie$6K
- Bayer$6K
- Pfizer$6K
- plus $14K from 21 others
Across 16 payments — averaging $923.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$8K
- Astrazeneca UK Limited$7K
What the payments were for
- Consulting fees$55,14883%
- Speaking & faculty fees$5,6008%
- Travel & lodging$3,6295%
- Food & beverage$2,3524%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $13,047 |
| Regeneron | 18 | $12,136 |
| Bristol Myers Squibb | 11 | $9,426 |
| AbbVie | 3 | $6,047 |
| Bayer | 8 | $6,031 |
| Pfizer | 6 | $5,600 |
| Merck | 3 | $5,119 |
| GSK | 1 | $2,600 |
| Fresenius Kabi USA, LLC | 7 | $2,436 |
| Johnson & Johnson | 5 | $1,755 |
| AstraZeneca | 3 | $1,124 |
| Astellas Pharma US Inc | 8 | $345 |
| Eisai Inc. | 3 | $268 |
| Organon | 1 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $150 |
| Cardinal Health 110 LLC | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Beigene USA, Inc. | 2 | $54 |
| Genentech USA, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Gilead | 1 | $23 |
| Sanofi | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.